Emil D. Kakkis Sells 11,727 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CEO Emil D. Kakkis sold 11,727 shares of the business's stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the transaction, the chief executive officer now directly owns 2,183,985 shares of the company's stock, valued at approximately $92,229,686.55. This trade represents a 0.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ultragenyx Pharmaceutical Trading Down 0.5 %

Shares of RARE traded down $0.20 during trading hours on Tuesday, reaching $42.07. 733,803 shares of the stock traded hands, compared to its average volume of 777,810. The company has a market cap of $3.88 billion, a P/E ratio of -6.50 and a beta of 0.56. The company's 50-day moving average price is $47.98 and its two-hundred day moving average price is $49.41. Ultragenyx Pharmaceutical Inc. has a 52-week low of $37.02 and a 52-week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The business had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. During the same period in the previous year, the business earned ($2.23) earnings per share. The business's revenue was up 42.3% on a year-over-year basis. On average, research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on RARE shares. Royal Bank of Canada reiterated an "outperform" rating and set a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. HC Wainwright reiterated a "buy" rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, December 24th. Wells Fargo & Company increased their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a report on Friday, December 20th. TD Cowen boosted their price target on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating on the stock in a research note on Thursday, November 21st. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average price target of $88.46.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC grew its position in shares of Ultragenyx Pharmaceutical by 103.8% during the second quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company's stock valued at $76,065,000 after purchasing an additional 942,529 shares in the last quarter. Alkeon Capital Management LLC boosted its stake in Ultragenyx Pharmaceutical by 34.3% during the third quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company's stock valued at $167,301,000 after buying an additional 769,884 shares during the last quarter. Two Sigma Advisers LP grew its holdings in Ultragenyx Pharmaceutical by 123.4% during the 3rd quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company's stock valued at $54,872,000 after buying an additional 545,600 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at approximately $17,468,000. Finally, Ikarian Capital LLC bought a new stake in Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $9,943,000. 97.67% of the stock is currently owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.